Neovasc

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neovasc Inc. is a specialty medical device company that develops and manufactures products for the rapidly growing cardiovascular device marketplace.Neovasc Inc. offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners.

VANCOUVER and MINNEAPOLIS, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022.  A recorded presentation by Fred Colen, Neovasc's Chief Executive Officer, will be available on the conference website starting at 7:00 am EST on Monday, January 10.  The recording will be archived for 90 days.

Neovasc to Participate in H.C. Wainwright BIOCONNECT Virtual Conference

COSIRA-II Trial Designed to Study the Neovasc Reducer(TM) for Patients with Refractory AnginaVancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 5, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced enrollment of the first patient in the COSIRA-II clinical trial. COSIRA-II (COronary SInus Reducer for the Treatment of Refractory Angina) is a pivotal trial that will study the Neovasc Reducer™ ("Reducer"), designed to reduce angina symptoms in patients with refractory angina. The results of this study will complement existing international safety...

Neovasc Announces First Patient Enrollment in COSIRA-II Trial

VANCOUVER and MINNEAPOLIS, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that its management team will be participating in the Sidoti December Virtual Microcap Conference to be held December 8-9, 2021.  Fred Colen, President and Chief Executive Officer, will give a presentation on Wednesday, December 8 at 3:15 pm EST.  A link to the live webcast of the presentation will be available in the Investor Relations section of the Neovasc website at https://www.neovasc.com/investors/ . The recording will be archived for 90 days.

Neovasc to Participate in Sidoti December Virtual Microcap Conference

First therapy to receive newly established French reimbursement designationVancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 30, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Neovasc Reducer™ ("Reducer") system has been granted Prise en Charge Transitoire ("PECT") reimbursement in France by the national health authority, Haute Autorité de Santé ("HAS"). The decision will be officialized upon publication in the French Journal Officiel.The Reducer is the first therapy to be approved under the newly established PECT process. It...

Neovasc Reducer(TM) System Receives National Reimbursement in France

First therapy to receive newly established French reimbursement designation

Neovasc Reducer™ System Receives National Reimbursement in France

VANCOUVER and MINNEAPOLIS, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Neovasc Inc.  ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN) has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq has granted an additional 180 calendar day period within which to evidence compliance with the $1.00 bid price requirement following the expiration of the current compliance period on November 22, 2021.

Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance

VANCOUVER and MINNEAPOLIS, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Neovasc  Inc. (“Neovasc” or the “Company”) ( NASDAQ ,  TSX : NVCN) today announced that the United Kingdom's Interventional Procedures Programme at the National Institute for Health and Care Excellence (“NICE”) has issued guidance supporting the implantation of the Neovasc Reducer™ (“Reducer”) in appropriate patients suffering from refractory angina, a painful and debilitating condition that causes chest pain when other treatment options have failed or are not possible.

The National Institute for Health and Care Excellence of The United Kingdom Provides Positive Guidance for Neovasc Reducer System

Neovasc (NVCN) delivered earnings and revenue surprises of -22.22% and -41.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Neovasc (NVCN) Reports Q3 Loss, Lags Revenue Estimates

Neovasc Inc. (NVCN) CEO Fred Colen on Q3 2021 Results - Earnings Call Transcript

VANCOUVER and MINNEAPOLIS, Nov. 09, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN) today reported financial results for the third quarter ended September 30, 2021.

Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update

VANCOUVER, Nov. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire –  Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on November 9, 2021.

Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021

Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Publication Highlights Device Success in Chronic Total Occlusions of the Right Coronary ArteryVancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 21, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN)  ("Neovasc" or the "Company") today announced that the Neovasc Reducer™ ("Reducer") is featured in an article published in the latest issue of the Polish Heart Journal. Entitled "Efficacy of Coronary Sinus Reducer Implantation in Patients with Chronic Total Occlusion of the Right Coronary Artery," the article's first author is Miha Mrak, M.D., University Medical Centre Ljubljana, Ljubljana, Slovenia.The publication...

Neovasc Reducer(TM) Featured in Polish Heart Journal

Publication Highlights Device Success in Chronic Total Occlusions of the Right Coronary Artery

Neovasc Reducer™ Featured in Polish Heart Journal

VANCOUVER and MINNEAPOLIS, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label clinical study (the REDUCER-I study)” in the September 2021 issue of the journal EuroIntervention.

Neovasc REDUCER-I Study Published in EuroIntervention Journal

The FDA approved the Investigational Device Exemption for Neovasc Inc's (NASDAQ:NVCN) COSIRA-II IDE Clinical Trial regarding the Neovasc Reducer. Related Content:   Real-World Study Shows Neovasc's Reducer Is Safe, Efficacious In Patients With Refractory Angina.

Why Are Neovasc Shares Moving Higher On Thursday?

Company on Schedule to Commence Trial Late This Year

Neovasc Announces FDA Approval of COSIRA-II Clinical Trial

VANCOUVER and MINNEAPOLIS, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire –  Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 23rd Annual H.C. Wainwright Global Investment Conference to be held September 13-15, 2021. A pre-recorded company presentation will be available beginning at 7:00 am EDT on September 13 through the conference website and the Investor Relations section of the Neovasc website at https://www.neovasc.com/investors/. The recording will be archived for 90 days.

Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference

VANCOUVER and MINNEAPOLIS, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA).  Following multiple productive discussions with FDA over the past several months, the protocol for the previously approved COSIRA-II study has been supplemented in consideration of additional experience and key questions arising from the October 2020 Circulatory Systems Devices Panel Meeting regarding the Neovasc Reducer™ (“Reducer”).

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

Neovasc (NVCN) delivered earnings and revenue surprises of 0.00% and -36.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Neovasc (NVCN) Reports Q2 Loss, Misses Revenue Estimates

Neovasc Inc. (NVCN) CEO Fred Colen on Q2 2021 Results - Earnings Call Transcript

VANCOUVER and MINNEAPOLIS, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN), today reported financial results for the second quarter ended June 30, 2021.

Neovasc Announces Second Quarter 2021 Financial Results

Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

VANCOUVER, July 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021.  Neovasc's President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 pm EDT.

Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021

Neovasc Team Grows with Addition of Industry Veterans Lisa Becker as VP, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as VP of Clinical Affairs

News for Neovasc Stock (NVCN)